Compare Agnico Eagle Mines Ltd (AEM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Moderna, Inc. — how do they compare? Agnico Eagle Mines Ltd trades at $144.29 (market cap $75.10B), while Moderna, Inc. trades at $74.43 (market cap $31.65B). The key difference: Agnico Eagle Mines Ltd is far larger — about 2.4× Moderna, Inc.'s market cap, and Agnico Eagle Mines Ltd pays a 1.2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AEM | MRNA | |
|---|---|---|
Market Cap | $75.10B | $31.65B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $81.80 |
52-Week Low | $116.14 | $22.36 |
Enterprise Value | $72.30B | $27.74B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
Moderna (MRNA) trades at $79.77, up 0.01% on the day, with a bullish technical signal from moving averages and positive momentum from recent pipeline news. The stock has seen significant gains, driven by FDA progress on its mRNA flu vaccine and expansion into oncology and rare diseases. However, fundamentals show persistent losses, with a net income margin of -144.92% in 2025 and declining revenue from pandemic peaks, though quarterly EPS has beaten expectations recently.
The outlook is mixed: strong technical momentum and pipeline diversification offer upside, but high valuation ratios and sustained unprofitability pose risks. Analyst consensus is cautious with a $48.83 price target, suggesting 39% downside, indicating Wall Street sees limited near-term fundamental support despite recent bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
